Itraconazole for dogs is a prescription-only medicine (POM-V) from the triazole antifungal family, given orally at roughly 5 mg/kg once daily, prescribed off-label under the veterinary cascade to treat yeast (Malassezia) skin and ear disease, ringworm, and deep systemic fungal infections. It is not a supplement, it cannot be bought over the counter, and it is not interchangeable between formulations — a randomised crossover study in Beagles found that compounded itraconazole delivered only 5.52% of the drug exposure of the reference capsule, which is why compounding is specifically advised against in dogs. If your vet has just prescribed it, the two things that matter most are giving it with food and understanding that the dose on the label is a starting point, not a fixed number.
This guide covers what the drug does, what the veterinary trials actually measured, the dosing quirk that halves drug exposure without halving results, and where itraconazole sits against the other antifungals your vet might have considered.
What itraconazole is and what it treats
Itraconazole belongs to the triazole family. Like every azole, it blocks lanosterol 14-alpha-demethylase — the enzyme encoded by the ERG11 gene — which fungi need to build ergosterol, the sterol that keeps their cell membrane intact. Starve the membrane of ergosterol and the organism stops replicating.
What separates itraconazole from its cousins is where it goes. It is strongly lipophilic and highly protein-bound, so it concentrates in keratin, sebum and the stratum corneum, and stays there for days to weeks after the last dose. That tissue persistence is the single fact that explains most of its dosing behaviour.
In UK practice it is commonly reached for in four situations:
- Stubborn Malassezia dermatitis and otitis — usually after topical therapy alone has failed, or when too much skin surface is involved to treat topically. Most routine yeast cases never need it; see our overview of dog yeast infection for where oral drugs sit in the wider picture.
- Dermatophytosis (ringworm), including nail-bed infections, where itraconazole’s keratin affinity is a genuine advantage over fluconazole — covered in its own section below.
- Deep systemic mycoses — blastomycosis, histoplasmosis and cryptococcosis. These are uncommon presentations, but itraconazole is a mainstay of treatment when one is diagnosed.
- Cutaneous protothecosis and other rarities, where the evidence base is case reports rather than trials.
It is not an antibacterial. A dog with a mixed staphylococcal and yeast infection — which is the majority of chronically itchy dogs — will not be fully treated by itraconazole alone.
Itraconazole dosage for dogs
Only your vet sets the dose. The figures below are the published ranges you will see in the veterinary literature, given so you can follow the conversation, not so you can dose at home.
| Situation | Published regimen | Source of the number |
|---|---|---|
| Malassezia dermatitis — daily | 5 mg/kg orally every 24 h for 21 days | Pinchbeck et al., JAVMA 2002 (control arm) |
| Malassezia dermatitis — pulse | 5 mg/kg orally every 24 h on 2 consecutive days per week, for 3 weeks | Pinchbeck et al., JAVMA 2002 (pulse arm) |
| Malassezia dermatitis — 28-day comparator | 5 mg/kg orally once daily for 28 days | Lee et al., Veterinary Dermatology 2024 |
| Blastomycosis — starting dose | 5 mg/kg/day, then adjusted to serum concentration | Reinhart et al., JVIM 2026 |
| General range quoted in drug references | 5–10 mg/kg/day, daily or split every 12 h | Merck Veterinary Manual; VCA Animal Hospitals |
Give it with food, and preferably a fatty meal. Itraconazole is a poorly soluble, pH-dependent compound; absorption from the capsule improves substantially when it is not given on an empty stomach. This is one of the few things an owner fully controls, and it is the most common reason a correctly prescribed course underperforms.
Doses above 10 mg/kg deserve particular attention, because that is where the drug’s most distinctive adverse effect appears — covered below.
The pulse-therapy result most articles skip
Pinchbeck and colleagues at Ohio State ran a randomised controlled trial in 20 dogs with Malassezia pachydermatis skin and ear infection, published in JAVMA in 2002. Ten dogs received 5 mg/kg daily for 21 days. Ten received the same 5 mg/kg but only on 2 consecutive days per week for 3 weeks — roughly a third of the total drug.
Both groups improved significantly by day 21, and the difference between groups was not statistically significant for clinical severity, skin cytology or skin culture. The pulse group actually showed a significantly greater decrease in ear culture scores than the daily group.
Why would a third of the drug work as well? Because of the tissue persistence described earlier: itraconazole keeps working in the skin long after plasma levels fall. The practical consequence — less total drug exposure, lower cost, fewer hepatic and cutaneous adverse events — is the kind of thing worth asking your vet about directly if a long course is proposed.
Two honest limits, which the authors themselves flagged. The trial was small (20 dogs), so it was not powered to detect modest differences. And ear cytology scores did not significantly improve in either group by day 21; the authors concluded that dogs with Malassezia otitis may need adjunctive treatment. If your dog’s problem is primarily ears, oral therapy alone was not enough in this study — which is why topical protocols still lead in dog ear yeast infection management.
The compounded itraconazole trap
This is the finding that should change what you do at the dispensary counter, and almost no consumer article mentions it.
Mawby and colleagues at the University of Tennessee ran a randomised, three-way, three-period crossover in nine healthy Beagles (JVIM, 2014). Each dog received 100 mg of itraconazole — averaging 10.5 mg/kg — as either the innovator brand capsule, an approved human generic capsule, or itraconazole compounded in a commercially available compounding vehicle.
| Formulation | AUC vs reference | CMAX vs reference | Verdict |
|---|---|---|---|
| Innovator (brand) capsule | Reference | Reference | — |
| Approved human generic capsule | 104.2% | 86.34% | Not formally bioequivalent, but exposure similar enough that therapeutic concentrations could be achieved |
| Compounded itraconazole | 5.52% | 4.14% | Authors' conclusion: “unlikely to be effective… should not be used in dogs” |
Neither test formulation met formal bioequivalence criteria. But the gap between them is the whole story: the generic behaved like real medicine, while the compounded liquid delivered roughly one-twentieth of the drug exposure. A dog on compounded itraconazole can look, to an owner and to a vet, like a dog whose infection is drug-resistant — when the actual problem is that almost none of the drug ever reached the bloodstream.
Specially prepared liquid itraconazole is often suggested for small dogs, because capsules are hard to split accurately and a liquid is easier to measure. If it is offered to you, this is a reasonable and specific question to ask: is there a way to dose an authorised capsule instead? Under the cascade, your veterinary surgeon has to justify each step away from an authorised product, so the question is a fair one to put.
Ringworm and nail-bed infection: where itraconazole earns its place
If there is one indication where itraconazole is chosen over the cheaper triazoles on pharmacological grounds rather than habit, it is dermatophytosis — ringworm — and infection of the nail bed.
The reason is the property described at the top of this article. Itraconazole is strongly lipophilic and binds avidly to keratin, so it accumulates in exactly the tissue dermatophytes live in: hair shafts, the outer layer of the skin and the claw. Fluconazole, which is water-soluble, distributes well into body water, urine and the eye but does not build the same keratin reservoir, which is why the 2024 head-to-head result showing the two drugs equivalent for Malassezia dermatitis should not be read across to ringworm. They are equivalent for the yeast on the skin surface, not for the fungus growing inside the keratin.
Three practical points follow from that.
- Nail-bed infection is a long job. Claw tissue is replaced slowly, so an infected nail bed generally needs a longer course than skin-only disease, and improvement is judged by new growth rather than by the appearance of the existing claw.
- Systemic treatment is normally paired with topical treatment. Oral therapy deals with the fungus in the animal; clipping, antifungal washes and cleaning the environment deal with the infected hairs being shed around the house, which is what drives reinfection.
- Ringworm is zoonotic. It passes to people, particularly children and anyone immunosuppressed, so it is handled as a household problem rather than a dog problem. Bedding, brushes and soft furnishings matter as much as the dose.
Diagnosis should come before the prescription. A ringworm-shaped lesion is not proof of ringworm — demodicosis, bacterial folliculitis and localised allergic disease can look identical, and each needs a different drug. Fungal culture, PCR or trichography is what settles it, and starting a triazole on appearance alone risks weeks lost to the wrong treatment.
Why your vet may want a blood level
Itraconazole serum concentrations vary widely between individual dogs on identical doses. Reinhart and colleagues (JVIM, 2026) followed 14 dogs with blastomycosis started at 5 mg/kg/day, with therapeutic drug monitoring at two weeks and monthly thereafter, targeting trough concentrations of 2–7 µg/mL.
- 12 of 14 dogs needed at least one dose adjustment, and nine needed further adjustments even after hitting target.
- There was no correlation between dose and serum concentration (r = 0.080, P = 0.43). You cannot predict the blood level from the milligrams.
- Dogs were treated for a median of 7.9 months (range 2.6–9.9).
- The median dose at remission (2.8 mg/kg/day) was significantly lower than the starting dose (4.9 mg/kg/day; P < 0.001).
- All 14 dogs achieved remission, with one antigenic relapse.
That study followed a deep systemic mycosis, but the pharmacokinetic lesson generalises: dose does not predict blood level in this drug. Two takeaways follow. First, monitoring is not upselling — it is how the dose gets to be right for your individual dog. Second, the dose often needs to come down over a long course, which matters because itraconazole’s worst effects are concentration-dependent.
Side effects and what to watch for
| Effect | What it looks like | What to do |
|---|---|---|
| Gastrointestinal upset | Reduced appetite, vomiting, loose stools, lethargy | Common and often dose-related; report it, do not simply stop the drug |
| Hepatotoxicity | Rising ALT, poor appetite, jaundice (yellow gums or eye whites), vomiting | Stop and phone your vet the same day if jaundice appears; liver values are usually monitored during long courses |
| Ulcerative dermatitis from vasculitis | Painful ulcerated skin lesions appearing during treatment | Described in drug references as dose-related and largely seen above 10 mg/kg — a reason to phone rather than wait (Merck Veterinary Manual) |
| Drug interactions | Itraconazole inhibits cytochrome P450 enzymes and can raise levels of other drugs | Give your vet a full list of medications and supplements before starting |
| Pregnancy and nursing | — | Not recommended |
The vasculitis picture is the one worth memorising, because it looks like a skin problem getting dramatically worse rather than like a drug side effect — and an owner’s instinct may be to assume the infection is winning.
Itraconazole against the other antifungals
Two 2024–2025 studies sharpen this comparison considerably.
Lee and colleagues (Veterinary Dermatology, 2024) randomised 61 client-owned dogs with Malassezia dermatitis to fluconazole 5 mg/kg (n = 20), fluconazole 10 mg/kg (n = 17) or itraconazole 5 mg/kg (n = 16), once daily for 28 days. All three groups showed significant reductions in mean yeast count, clinical index score and pruritus scores, and there was no significant difference between the groups. The authors concluded fluconazole is as effective as itraconazole for this indication — useful, since fluconazole for dogs is generally cheaper and has a different side-effect profile.
Domán and colleagues (Antibiotics, 2025) tested 87 clinical M. pachydermatis isolates from dogs and cats by broth microdilution. Ketoconazole, itraconazole and terbinafine showed the highest activity; miconazole and clotrimazole showed reduced activity. Whole-genome sequencing of ten isolates found SNPs in ergosterol-pathway genes including ERG11 and ERG1, with one substitution (K446R in ERG11) present only in higher-MIC isolates — though the authors were careful to state that no direct correlation with resistance could be unequivocally established.
| Drug | Strongest use case | Main limitation |
|---|---|---|
| Itraconazole | Keratin and skin reservoir; ringworm, nail beds, deep mycoses | Wide inter-dog variability; dose-related vasculitis above 10 mg/kg; compounded forms fail |
| Fluconazole for dogs | Water-soluble; reaches CNS, urine and eye; equal to itraconazole for Malassezia in Lee 2024 | Poor choice for ringworm |
| Ketoconazole for dogs | Long track record, low cost, high in-vitro activity | More hepatic and endocrine effects than newer triazoles |
| Miconazole for dogs | Topical shampoos and ear preparations | Reduced in-vitro activity in Domán 2025; not a systemic option |
| Chlorhexidine for dogs | Topical antiseptic; the backbone of most yeast shampoo protocols | Contact time dependent; surface only |
Negre and colleagues’ systematic review in Veterinary Dermatology (2009) remains the reference point for interpreting all of this: the best-supported intervention for canine Malassezia dermatitis was a topical protocol — 2% miconazole with 2% chlorhexidine shampoo — with the evidence for systemic azoles weaker than the evidence for that topical regimen. Oral itraconazole is an escalation, not a default.
Where a supplement fits, and where it does not
Nothing sold without a prescription treats a deep fungal infection, ringworm or an established Malassezia infection. Current research does not establish that any supplement ingredient clears an established Malassezia infection in a dog. Anyone telling you otherwise is selling past the evidence.
What a well-built supplement can reasonably address is the part of the problem that keeps bringing dogs back: the terrain. Yeast overgrowth in dogs is usually secondary to something — allergic skin disease, a compromised barrier, moisture, endocrine disease. The drug clears the current bloom; it does nothing about why the bloom happened. That is the pattern behind recurring yeast infection in dogs.
Our dog yeast infection treatment drops are a complementary pet food, built for that maintenance role rather than as a drug substitute. Because we publish the formulation rather than hiding behind “proprietary blend”, the comparison below is one you can verify against our label:
| What to check on a label | Common market practice | Pure Majesty (V15, published figures) |
|---|---|---|
| Total active load disclosed | Often a proprietary blend with no per-ingredient amounts | ~292 mg of actives per mL, itemised |
| Strategy | Usually a single axis (one antifungal herb, or probiotics alone) | Three axes — antifungal pressure, gut and immune support, skin-barrier support — across 19 actives |
| Yeast-organism ingredient form | Live-CFU probiotic counts, which decay with storage and shipping | S. boulardii as a postbiotic, so the amount on the label is the amount delivered |
| Dose control | Fixed-size chew — a 5 kg dog and a 35 kg dog often get the same unit | Liquid, titrated by body weight |
| Batch verification | Rarely published | Certificate of analysis per batch |
A better label is not the same thing as a proven clinical outcome, and we would rather say so than imply otherwise. If your dog is on prescribed itraconazole, tell your vet about any supplement before adding it — azoles interact with a long list of compounds through cytochrome P450. Other options for the maintenance phase are gathered in our yeast relief collection, alongside the rest of our natural dog supplements.
When to phone your vet
- Yellowing of the gums, eye whites or skin at any point during treatment — same day.
- New ulcerated, painful skin lesions appearing after starting the drug — same day.
- Persistent vomiting, refusal to eat for more than 24 hours, or marked lethargy.
- Circular areas of hair loss or scaling in the dog, especially if a person in the household develops a similar itchy ring-shaped rash — ringworm is treated as a household problem.
- No visible improvement after three to four weeks on a correctly given course — this is the moment to ask about the formulation and about a serum level, not to assume the drug has failed.
Before any oral antifungal is started, the diagnosis should rest on cytology — tape or swab samples read under the microscope — not on appearance alone. Distinguishing yeast from bacterial infection and from pure allergy matters, because the treatments differ entirely; see dog yeast infection vs allergies.
Frequently asked questions
How long does itraconazole take to work in dogs?
For Malassezia dermatitis, the published trials measured meaningful improvement in clinical scores and yeast counts by day 14, with further improvement by day 21–28. Deep systemic mycoses take far longer: treatment ran a median of 7.9 months in the 2026 monitoring study. Finish the full prescribed course even if your dog looks well.
Should itraconazole be given with food?
Yes. Absorption is pH-dependent and improves considerably when the capsule is given with a meal, ideally one containing fat. This is the single most common owner-controllable reason a course underperforms.
Is compounded itraconazole safe for dogs?
Safety is not the issue — effectiveness is. In the 2014 Beagle crossover study, compounded itraconazole produced only 5.52% of the reference formulation’s drug exposure, and the authors concluded it should not be used in dogs. Ask your vet about dosing an authorised capsule instead.
Can I buy itraconazole for my dog without a prescription?
No. In the UK it is a prescription-only medicine (POM-V), supplied on a veterinary prescription and used off-label in dogs under the cascade, with dose-related liver and skin toxicity. It also requires a diagnosis first — giving an antifungal to a dog whose problem is bacterial or allergic delays the treatment that would have worked.
Itraconazole or fluconazole for a yeast infection?
For Malassezia dermatitis specifically, the 2024 randomised study in 61 dogs found no significant difference between fluconazole at 5 or 10 mg/kg and itraconazole at 5 mg/kg over 28 days. For ringworm or nail-bed infection, itraconazole is generally the better choice because it concentrates in keratin. Your vet will weigh cost, other medications and your dog’s liver values.
Does my dog need blood tests while on itraconazole?
For short skin courses, liver values are often checked before and during treatment. For long courses and for systemic mycoses, serum drug concentrations may also be measured, because dose does not predict blood level — the 2026 study found no correlation at all (r = 0.080, P = 0.43), and 12 of 14 dogs needed a dose change.
Can itraconazole treat ringworm in dogs?
It is one of the standard systemic options for dermatophytosis, and its keratin affinity is why it is preferred over fluconazole for that indication. Ringworm is contagious to people, so it is treated as a household problem, not just a dog problem.
UK guidance
For UK-specific advice, read PDSA's guidance on PDSA Pet Health Hub, written for UK pets. If your dog's signs are new, persistent or worsening, speak with a vet; this article is general information, not a diagnosis.
Scientific References
- Pinchbeck LR, Hillier A, Kowalski JJ, Kwochka KW. Comparison of pulse administration versus once daily administration of itraconazole for the treatment of Malassezia pachydermatis dermatitis and otitis in dogs. J Am Vet Med Assoc. 2002;220(12):1807-1812. PMID: 12092953. doi:10.2460/javma.2002.220.1807
- Mawby DI, Whittemore JC, Genger S, Papich MG. Bioequivalence of orally administered generic, compounded, and innovator-formulated itraconazole in healthy dogs. J Vet Intern Med. 2014;28(1):72-77. PMID: 24428315. doi:10.1111/jvim.12219
- Lee H, Koo Y, Yun T, et al. A single-blind randomised study comparing the efficacy of fluconazole and itraconazole for the treatment of Malassezia dermatitis in client-owned dogs. Vet Dermatol. 2024;35(3):284-295. PMID: 38169074. doi:10.1111/vde.13233
- Reinhart JM, Leduc F, Hanzlicek A, et al. Therapeutic drug monitoring of itraconazole in treatment of blastomycosis in dogs. J Vet Intern Med. 2026;40(1):aalag029. PMID: 41742595. doi:10.1093/jvimsj/aalag029
- Domán M, Első D, Pintér K, et al. Antifungal susceptibility of Malassezia pachydermatis isolates from companion animals and genomic insights into resistance mechanisms. Antibiotics (Basel). 2025;14(9):902. PMID: 41009881. doi:10.3390/antibiotics14090902
- Negre A, Bensignor E, Guillot J. Evidence-based veterinary dermatology: a systematic review of interventions for Malassezia dermatitis in dogs. Vet Dermatol. 2009;20(1):1-12. PMID: 19152584
- Merck Veterinary Manual. Antifungals for Integumentary Disease in Animals. merckvetmanual.com. Accessed August 2026.
- VCA Animal Hospitals. Itraconazole. vcahospitals.com/know-your-pet/itraconazole. Accessed August 2026.
This article is educational and does not replace veterinary care. Itraconazole is a prescription-only medicine (POM-V) in the UK, regulated by the Veterinary Medicines Directorate and used off-label in dogs under the veterinary cascade; dosing, monitoring and duration must be set by your veterinary surgeon. Pure Majesty Pets products are complementary pet foods, not veterinary medicines; they are not authorised by the Veterinary Medicines Directorate to diagnose, treat, cure or prevent any disease, and they are not a substitute for prescribed antifungal therapy.